US Sales of Sanofi/Regenerons Dupilumab for Atopic Dermatitis Could Exceed $1.3 Billion by 2022
The first biologic to treat atopic dermatitis, Sanofi and Regeneron’s dupilumab, could launch in the US by Q2 2017, and the potentially game-changing drug could achieve annual sales of over $1.3 billion in this market by 2022, according to an analyst with research and consulting firm GlobalData.
Following impressive top-line Phase IIb safety and efficacy data in moderate-to-severe atopic dermatitis patients in July 2014, dupilumab has been assigned a Breakthrough Therapy designation by the FDA.
Abhilok Garg, PhD, GlobalData’s Analyst covering Immunology, states that if dupilumab’s ongoing Phase III trials, which were initiated in September and October this year, are positive and the drug gains regulatory approval in the US, it will enter a market where there are currently no biologics and few effective options for moderate-to-severe atopic dermatitis patients.
Garg explains: “These patients must commonly resort to cyclosporine when a systemic agent is required, but cyclosporine is not a viable long-term maintenance treatment, due to the risk of nephrotoxicity associated with its prolonged use.
“If first to market, dupilumab would gain a competitive edge and the opportunity to set a precedent in terms of price. The drug’s path to approval is therefore being closely watched by other drug manufacturers, such as Bristol-Myers Squibb. This company is developing BMS-981164, an anti-interleukin-31 biologic about which leading dermatologists have expressed excitement.”
Following its launch, GlobalData envisions little competition for dupilumab, due to the lack of topical treatments’ popularity among most atopic dermatitis patients and the strong efficacy of the drug in its target patient segment. Furthermore, the treatment may also prove able to treat other, often connected conditions.
Garg comments: “Simultaneous late-stage trials assessing dupilumab’s potential as a treatment for nasal polyps and asthma are currently underway. These diseases commonly present in patients with atopic dermatitis in a phenomenon known as the atopic march.
“A drug that is able to target all of these related diseases would likely gain payer backing and a strong foothold across the major pharmaceutical markets, as its manufacturer could justify a premium price on the basis that this single product can control more than one of these highly prevalent chronic conditions.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance